VACCINE INJURY COMPENSATION MECHANISM FOR ADVERSE EVENTS CAUSED BY COVID-19 VACCINES IN SOUTHEAST ASIAN COUNTRIES
DOI:
https://doi.org/10.46754/umtjur.v5i2.412Keywords:
vaccine injury, compensation, vaccine, VICP, COVID-19Abstract
Adverse Events Following Immunization (AEFI) or vaccine injury is an issue of great concern in many nations, including Malaysia. This issue has long attracted the public’s interest, but the emergence of COVID-19 disease has triggered greater interest as nations engaged in mass vaccination programs for their citizens. This is further exacerbated by the growing dissatisfaction with the traditional tort litigation system which necessitates exploring alternative ways to deal with vaccine injury cases. While the vaccine injury compensation program (VICP) has been implemented in several countries to compensate affected individuals following vaccination, not all VICP can cater to public health emergencies, especially regarding vaccine COVID-19. Malaysia, for example, has a similar program known as Special Financial Assistance (SFA) Adverse Effects of COVID-19 Vaccine, which allows individuals to receive financial assistance if they suffer from AEFI of COVID-19. Thus, this paper is intended to review and analyse the VICP in Southeast Asian countries and its implementation in Malaysia. It is important to explore these VICP to strengthen the existing processes in terms of accountability and compensation. This qualitative research was based on document review and comparative methodologies by exploring the VICP in Southeast Asia and similar mechanism in Malaysia to enrich the subject matter of the vaccine COVID-19 liability. The finding shows that the VICP program seems to be a great alternative in dealing with vaccine injury cases, especially in addressing the growing dissatisfaction with the traditional tort litigation system. Malaysia, Singapore, and Thailand has its own VICP for affected individuals with COVID-19 vaccines while Myanmar, Cambodia, Timor-Leste, Indonesia, Vietnam, and the Philippines are under COVID-19 vaccine injury compensation scheme by COVID-19 Vaccines Global Access (COVAX) offered in 92 low- and middle-income nations.
References
Abdullah, Z. (2023, January 27). 413 people get COVID-19 vaccine injury payouts, over $1.8m paid or offered to applicants: MOH. The Straits Times. https://www.straitstimes. com/singapore/health/413-people-qualify-for-covid-19-vaccine-injury-payouts-as-at-end-2022
Bateman, C. (2012). Bogus neurosurgeon beats system hands down. South African Medical Journal, 102(3), 626-627.
Berns, S. T. (2022). Immunization and indemnification: rethinking the US approach to liability protections for vaccine manufacturers during the COVID-19 Pandemic. International & Comparative Law Review, 9(2), 62–98.
Charles, S. (2001). Coping with a malpractice suit. Coping with a Malpractice Suit, 174(1), 55–58.
Charoensuthipan, P. (2021, September 29). B230m paid out in jab compensation. Bangkok Post. https://www.bangkokpost. com/thailand/general/2188543/b230m-paid-out-in-jab-compensation
Chatarin Phusae, M. R. (2018). A study on the preliminary compensation of no-fault compensation system to patients for injuries from medical services in Thailand [Assumption University]. https://repository. a u . e d u / s e r v e r / a p i / c o r e / b i t s t r e a m s / cfd64176-269c-4485-8510-06a30513334f/ content
Chuong, K. H., Rotella, A., Cooper, E. J., & O’Doherty, K. C. (2023). Public engagement on childhood vaccination: Democratizing policy decision-making through public deliberation. In Democratizing risk governance: Bridging science, expertise, deliberation and public values (pp. 271- 301). Cham: Springer International Publishing.
COVIDNOW. (2021). Vaccinations in Malaysia - COVIDNOW. https://covidnow.moh.gov.my/vaccinations
Crum, T., Tiwari, B. R., & Mooney, K. (2021). Current situation of vaccine injury compensation program and a future perspective in light of COVID-19 and emerging viral diseases. F1000Research, 10, 652. https://doi.org/10.12688/ F1000RESEARCH.51160.2
Douglas, T. (2009). Medical injury compensation: Beyond “no-fault”. Medical Law Review, 17(1), 30–51. https://doi.org/10.1093/ medlaw/fwn022
Errico, S. D., Zanon, M., Concato, M., Peruch, M., Scopetti, M., Frati, P., Fineschi, V., D’errico, S., Zanon, M., Concato, M., Peruch, M., Scopetti, M., Frati, P., & Fineschi, V. (2021). “First Do No Harm”. no-fault compensation program for COVID-19 vaccines as feasibility and wisdom of a policy instrument to mitigate vaccine hesitancy. Vaccines, 9(10), 1–14. https://doi.org/10.3390/vaccines9101116
Fairgrieve, D., Holm, S., Howells, G., Kirchhelle, C., & Vanderslott, S. (2021). In favour of a bespoke COVID-19 vaccines compensation scheme. The Lancet Infectious Diseases, 21(4), 448–450. https://doi.org/10.1016/ S1473-3099(21)00065-7
Fei, L., & Peng, Z. (2017). No-fault compensation for adverse events following immunization: A review of Chinese law and practice. Medical Law Review, 25(1), 99–114. https://doi.org/10.1093/medlaw/ fwx001
Feng, J., & LI, Q. (2021). How to ensure vaccine safety: An evaluation of China’s vaccine regulation system. Vaccine, 39(37), 5285–5294. https://doi.org/10.1016/j. vaccine.2021.07.081
Galasintu, S., & Loveera, C. (2021). The comparative study on consumer protection laws in ASEAN. Kasetsart Journal of Social Sciences, 42(4), 804-809. https://doi. org/10.34044/j.kjss.2021.42.4.13
Gavi, S. (2021). The COVAX No Fault Compensation Programme: Explained. VaccinesWork. https:// www.gavi.org/vaccineswork/covax-no-fault-compensation-programme-explained?gclid=Cj0KCQiA-K2MBhC-ARIsAMtLKRsKyKjPXwRb7chjVMwSK UUafOCMytqK7GSM1JfdbgqMvHe6WY x6N30aAmEXEALw_wcB
Glassman, V. B., & Lewis, T. (2022). Listen to your doctor: Examining the judicialization of student conduct administration through the lens of physicians’ medical malpractice stress. College Student Affairs Journal, 40(1), 32-48.
Goldberg, R. (2022). Vaccine liability in the light of COVID-19: A Defence of risk–benefit. Medical Law Review, 30(2), 243-267. https://doi.org/10.1093/medlaw/fwab053
Goodyear-Smith, F., & Ashton, T. (2019). New Zealand health system: Universalism struggles with persisting inequities. The Lancet, 394(10196), 432–442. https://doi. org/10.1016/S0140-6736(19)31238-3
Goudkamp, J. (2018). Pharmaceutical products liability in the United Kingdom. Pharmaceuticals Policy and Law, 20(1- 4), 115–129. https://doi.org/10.3233/PPL- 180469
Halabi, S. F. (2021). Solving the pandemic vaccine product liability problem. UC Irvine Law Review, 12, 11–2021. https:// scholarship.law.uci.edu/ucilrhttps:// scholarship.law.uci.edu/ucilr/vol12/iss1/7
Halabi, S., Heinrich, A., & Omer, S. B. (2020). No-fault compensation for vaccine injury - The other side of equitable access to COVID-19 Vaccines. The New England Journal of Medicine, 383(23), e125. https:// doi.org/10.1056/NEJMP2030600
Halabi, S., Ginsbach, K., Gottschalk, K., Monahan, J., & Murungi, J. (2022). No- Fault vaccine injury compensation systems adopted pursuant to the COVID-19 public health emergency response. Emory International Law Review, 37(1), 55.
Henry, M. L., Larkin, M. E., & Pike, E. R. (2015). Just compensation: A no-fault proposal for research-related injuries. Journal of Law and the Biosciences, 2(3), 645–668. https:// doi.org/10.1093/JLB/LSV034
HRSA. (2010). Developing a comprehensive national vaccine injury compensation program research report. Health Resources and Services Administration.
HRSA. (2021a). About the national vaccine injury compensation program. Official Web Site of the U.S. Health Resources & Services Administration. https://www.hrsa. gov/vaccine-compensation/about/index. html
HRSA. (2021b). Covered vaccines. Health Resources & Service Administration. https: //www.hrsa.gov/vaccine-compensation/ covered-vaccines/index.html
JKJAV. (2021). What is the procedure to apply for financial compensation for severe COVID-19 adverse effects? Ministry of Science, Technology, and Innovation. https://citf.mosti.gov.my/faq/en/docs/ special-issues/what-is-the-procedure-to-apply-for-financial-compensation-for-severe-covid-19-adverse-effects/
Kapp, M. (2016). Defensive medicine: No wonder policymakers are confused. International Journal of Risk & Safety in Medicine, 28(4), 213-219. https://doi. org/10.3233/JRS-170733
Kapp, M., & Reschovsky, J. (2018). Malpractice claim fears and the costs of treating Medicare patients: A new approach to estimating the costs of defensive medicine. Health Services Research, 28(3), 1498-516.
Kassim, P. N. (2014). No-fault compensation for medical injuries: Trends and challenges. Medicine and Law, 33(4). https://pubmed. ncbi.nlm.nih.gov/27351046/
Katz, E. D. (2019). Defensive medicine : A case and review of its status and possible solutions. Clinical Practice and Cases in Emergency Medicine, 3(4), 329–332. https:// doi.org/10.5811/cpcem.2019.9.43975
Kelly H. A., & Looker, C. I. D. (2011). A no-fault compensation scheme for serious adverse events attributed to vaccination. The Medical Journal of Australia, 195(1), 4–5.
Knol Radoja, K. (2019). Vaccine injury - Burden of proof of the defect and the causal link in the light of the judgment in the case C-621/15. EU and Comparative Law Issues and Challenges Series (ECLIC), 3, 255– 274. https://doi.org/10.25234/eclic/9002
Lookera, C., & Kellya, H. (2011). No-fault compensation following adverse events attributed to vaccination: A review of international programmes. Bulletin of the World Health Organization, 89(5), 371. https://doi.org/10.2471/BLT.10.081901
Luk, A., Clarke, B., Dahdah, N., Ducharme, A., Krahn, A., McCrindle, B., Mizzi, T., Naus, M., Udell, J. A., Virani, S., Zieroth, S., & McDonald, M. (2021). Myocarditis and pericarditis after COVID-19 mRNA vaccination: Practical considerations for care providers. Canadian Journal of Cardiology, 37(10), 1629-1634. https://doi. org/10.1016/J.CJCA.2021.08.001
Mahase, E. (2021). COVID-19: US suspends Johnson and Johnson vaccine rollout over blood clots. The BMJ. https://www.bmj. com/content/373/bmj.n970
Malay Mail. (2021, October 10). Health Minister: RM500,000 max compensation to anyone suffering severe side effects post COVID-19 vax. https://www.malaymail. com/news/malaysia/2021/03/22/health-minister-rm500000-max-compensation-to-anyone-suffering-severe-side-e/1959983
Mello, M. M. (2008). Rationalizing vaccine injury compensation. Bioethics, 22(1), 32–42. https://doi.org/10.1111/j.1467- 8519.2007.00590.x
MOH. (2021a). Clinical guidelines on COVID-19 vaccination in Malaysia (4th ed.). Ministry of Health, Malaysia.
MOH. (2021b). Update on applications and payments approved under vaccine injury financial assistance programme since May 2021. Ministry of Health Singapore. https:// www.moh.gov.sg/news-highlights/details/ update-on-applications-and-payments-approved-under-vaccine-injury-financial-assistance-programme-since-may-2021
MOH. (2021c). Vaccine injury financial assistance programme for COVID-19 vaccination (VIFAP). Ministry of Health Singapore. https://www.moh.gov.sg/covid- 19/vaccination/vifap
Mungwira, R. G., Guillard, C., Saldaña, A., Okabe, N., Petousis-Harris, H., Agbenu, E., Rodewald, L., & Zuber, P. L. F. F. (2020). Global landscape analysis of no-fault compensation programmes for vaccine injuries: A review and survey of implementing countries. PLoS ONE, 15(5).
NADMA. (2021). Special financial assistance adverse effects of COVID-19 vaccine. Agensi Pengurusan Bencana Negara (NADMA). https://www.nadma.gov.my/en/ assistance/bantuan-khas-kewangan-kesan-mudarat-vaksin-covid-19
Nguyen, T. B. A. (2019). No-fault versus strict liability compensation systems in medical malpractice law in Vietnam in comparision with Belgium, France, and England. Asian Journal of Law and Economics, 10(1). https://doi.org/10.1515/AJLE-2018-0004
NHSO. (2021a). Fairness and people’s safety: Our priority in the COVID-19 vaccination program. National Health Security Office. https://eng.nhso.go.th/view/1/ DescriptionNews/Fairness-and-peoples-safety-our-priority-in-the-COVID-19- vaccination-program/341/EN-US
NHSO. (2021b). NHSO offers no-fault compensation for vaccination’s adverse events. National Health Security Office. https://eng.nhso.go.th/view/1/ DescriptionNews/NHSO-offers-no-fault-compensation-for-vaccinations-adverse-events/343/EN-US
NPRA. (2016). Malaysian pharmacovigilance guidelines (2nd ed.). Ministry of Health Malaysia. http://npra.moh.gov.my
NPRA. (2021). Summary report on adverse events following immunisation of COVID-19 Vaccines in Malaysia. Ministry of Health Malaysia. https://www.npra.gov. my/index.php/en/health-professionals/ summary-report-on-covid-19-vaccines-aefis.html
Petah Wazzah, I. (2021, November 26). 93 permohonan bantuan khas kewangan kesan mudarat vaksin COVID-19. Utusan Malaysia. https://www.utusan.com.my/ covid-19/2021/11/93-permohonan-bantuan-khas-kewangan-kesan-mudarat-vaksin-covid-19/
Rahim, R. Vethasalam, R., & Gimino, G. (2023, June 7). COVID-19: Over RM2.5mil paid to 150 people who suffered serious side effects to vaccine, says Dr Zaliha. The Star. https://www.thestar.com.my/news/ nation/2023/06/07/covid-19-over-rm25mil-paid-to-150-people-who-suffered-serious-side-effects-to-vaccine-says-dr-zaliha
Rajneri, E., Borghetti, J.-S., Fairgrieve, D., & Rott, P. (2018). Remedies for damage caused by vaccines: A comparative study of four European legal systems. European Review of Private Law, 26(1), 57–95.
Rizzi, M., Attwell, K., Casigliani, V., Taylor, J., Quattrone, F., & Lopalco, P. (2021). Legitimising a ‘zombie idea’: Childhood vaccines and autism – the complex tale of two judgments on vaccine injury in Italy. International Journal of Law in Context, 17(4), 548-568. https://doi.org/10.1017/ S1744552321000586
Rodrigues, C. M. C., & Plotkin, S. A. (2020). Impact of vaccines: Health, economic and social perspectives. Frontiers in Microbiology, 11, 1526. https://doi. org/10.3389/FMICB.2020.01526
Salameh, M. J., Black, J. H., & Ratchford, E. V. (2018). Thoracic aortic aneurysm. Vascular Medicine (United Kingdom), 23(6), 573-578. https://doi. org/10.1177/1358863X18807760
Thompson, K. M., Orenstein, W. A., & Hinman, A. R. (2020). Performance of the United States Vaccine Injury Compensation Program (VICP): 1988–2019. Vaccine, 38(9), 2136-2143. https://doi.org/10.1016/J. VACCINE.2020.01.042
Vicky, N. K., & Papadimitriou, P. (2019). Vaccines in the pandemic era: Report on current issues on product liability from european law perspective. European Pharmaceutical Law Review (EPLR), 5(1), 57-62. https://doi.org/10.5772/ intechopen.86274
Wallis, K. (2013). New Zealand’s 2005 ’no-fault’ compensation reforms and medical professional accountability for harm. Journal of the New Zealand Medical Association, 126(1371), 33–44. https:// www.nzma.org.nz/journal-articles/new-zealands-2005-no-fault-compensation-reforms-and-medical-professional-accountability-for-harm
Watts, K., & Popa, T. (2021). Injecting fairness into COVID-19 vaccine injury compensation: No-fault solutions. Journal of European Tort Law, 12(1), 1–39. https://www.degruyter.com/document/ doi/10.1515/jetl-2021-0005/html
WHO. (2021a). Adverse events following immunization (AEFI). World Health Organization. https://www.who.int/teams/ regulation-prequalification/regulation-and-safety/pharmacovigilance/health-professionals-info/aefi
WHO. (2021b). No-fault compensation programme for COVID-19 vaccines is a world first. World Health Organization. https://www.who.int/news/item/22-02- 2021-no-fault-compensation-programme-for-covid-19-vaccines-is-a-world-first
WHO. (2021c). WHO issues emergency use listing for eighth COVID-19 vaccine. World Health Organization. https://www.who.int/news/item/03-11-2021-who-issues-emergency-use-listing-for-eighth-covid-19- vaccine
WHO. (2021d, July 28). Strategic framework for the South-East Asia regional vaccine action plan 2022−2030 as aligned with the global Immunization Agenda 2030. World Health Organization; World Health Organization. https://apps.who.int/iris/ bitstream/handle/10665/343756/sea-rc74- 8-eng.pdf
WHO. (2022). COVAX no-fault compensation program: Explained. World Health Organization. https://www.who.int/ initiatives/act-accelerator/covax/no-fault-compensation/covax-no-fault-compensation-program-explained
Wilder-Smith, A., Longini, I., Zuber, P. L., Bärnighausen, T., Edmunds, W. J., Dean, N., Spicher, V. M., Benissa, M. R., & Gessner, B. D. (2017). The public health value of vaccines beyond efficacy: methods, measures, and outcomes. BMC Medicine, 15(1), 1–9. https://doi.org/10.1186/S12916- 017-0911-8
Winter, J. D., Fletcher, C. L., Margolis, G., Winter, J. D., Fletcher, C. L., & Margolis, G. (2021). Vaccine-related liability: Past approaches, current challenges, and proposals for encouraging future innovation and more widespread vaccine use. Food and Drug Law Journal, 76(2), 270–317.
Wise, J. (2021). COVID-19: European countries suspend use of Oxford-AstraZeneca vaccine after reports of blood clots. The BMJ, 372(699). https://www.bmj.com/ content/372/bmj.n699/rapid-responses?int_ source=trendmd&int_medium=cpc&int_ campaign=usage-042019
Zuryani, Z., Zakuan, M., & Ismail, R. (n.d.). Health supplement and product liability in Malaysia: A call for reform. Malaysian Journal of Consumer and Family Economics, 30, 33-55.
Additional Files
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Universiti Malaysia Terengganu Journal of Undergraduate Research
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
